How would you approach metastatic NSCLC (adenocarcinoma without brain mets) with PD-L1 >50% and BRAF V600E driver mutation?

I would start with dabrafenib + trametinib based on what we know from available relevant trials and the literature.

-- Response rate for dabrafenib + trametinib as 1st-line therapy for people with BRAF V600E NSCLC was 64%.

-- Response rate for pembrolizumab as 1st-line therapy for people with NSCLC ...

Agree with starting BRAF/MEKi first and IO at progression. Trials are looking at combining the two strategies.